HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

The anti-HER2 antibody pertuzumab inhibits HER2 dimerization and affects HER2/HER3 dimer formation and signaling. As HER3 and its ligand neuregulin are implicated in pancreatic tumorigenesis, we investigated whether HER3 expression could be a predictive biomarker of pertuzumab efficacy in HER2(low)-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Thomas, GaëLle, ChardèS, Thierry, Gaborit, NadèGe, Mollevi, Caroline, Leconet, Wilhem, Robert, Bruno, Radosevic-Robin, Nina, Penault-Llorca, FréDéRique, Gongora, CéLine, Colombo, Pierre-Emmanuel, Lazrek, Yassamine, Bras-Goncalves, Rui, Savina, Ariel, Azria, David, Bazin, Hervé, PèLegrin, André, Larbouret, Christel
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2014
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4196190/
https://ncbi.nlm.nih.gov/pubmed/25216528
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados